admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to...

PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye...

MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board

PT270 – Dr. Rachel Yehuda – Research Trials and The Future...

Complete Results from Red Light Oregon Market Research in Oregon Show...

Cybin Granted DEA Schedule I Manufacturing License

MINDCURE Provides Update on Studies and Clinical Trials

The Missing Mushroom: Psychedelic Science and the Future of Psilocybin

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development...

1...183184185...218 Page 184 of 218

EDITOR PICKS

Dispatch from Breaking Convention 2025: Key Takeaways from Europe’s Largest Psychedelic...

Colorado’s Psilocybin Supply Chain Complete: First Testing Lab Licensed, Sessions Could...

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin